Serving teams that transform drug discovery and medicine

Drug discovery is slow, complex, and expensive. EMET changes that with faster, smarter preclinical research.

Leading teams trust BenchSci

BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform
BenchSci Announces Strategic Partnership with Thermo Fisher Scientific to Create AI-powered Tools to Accelerate R&D Productivity
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research

Pharmaceutical partners

Merck

Sanofi

Pfizer

Johnson & Johnson Innovative Medicine

Voyager Therapeutics

Novartis

Daiichi Sankyo

AbbVie

Academic institutions

University of Toronto

University of Cambridge

MIT

University of Oxford

Harvard University

University of Tokyo

ETH Zürich

Karolinska Institutet

Stanford University

University of Chicago

UCSF

University College London

Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.